NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $288,423 | -76.4% | 410,332 | -24.2% | 0.00% | – |
| Q4 2022 | $1,223,629 | -27.5% | 541,429 | +2.7% | 0.00% | -100.0% |
| Q3 2022 | $1,688,000 | -28.4% | 527,242 | -15.1% | 0.00% | 0.0% |
| Q2 2022 | $2,358,000 | -29.4% | 620,745 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $3,339,000 | -52.0% | 619,319 | +20.4% | 0.00% | -50.0% |
| Q4 2021 | $6,952,000 | +54.3% | 514,544 | +105.1% | 0.00% | +100.0% |
| Q3 2021 | $4,505,000 | +21.0% | 250,836 | +15.6% | 0.00% | 0.0% |
| Q2 2021 | $3,722,000 | -29.7% | 216,898 | -18.1% | 0.00% | -50.0% |
| Q1 2021 | $5,295,000 | +3.1% | 264,768 | -12.4% | 0.00% | 0.0% |
| Q4 2020 | $5,137,000 | -4.8% | 302,185 | -7.1% | 0.00% | 0.0% |
| Q3 2020 | $5,398,000 | -23.7% | 325,342 | +6.5% | 0.00% | -33.3% |
| Q2 2020 | $7,073,000 | +19.2% | 305,407 | -7.6% | 0.00% | 0.0% |
| Q1 2020 | $5,933,000 | -10.3% | 330,409 | +7.8% | 0.00% | 0.0% |
| Q4 2019 | $6,611,000 | -47.3% | 306,558 | -55.5% | 0.00% | -57.1% |
| Q3 2019 | $12,536,000 | -47.3% | 688,364 | +2.8% | 0.01% | -46.2% |
| Q2 2019 | $23,809,000 | +14.4% | 669,375 | +8.0% | 0.01% | +8.3% |
| Q1 2019 | $20,816,000 | +55.2% | 620,002 | +52.4% | 0.01% | +20.0% |
| Q4 2018 | $13,414,000 | -37.1% | 406,910 | +16.1% | 0.01% | -33.3% |
| Q3 2018 | $21,326,000 | +44.0% | 350,357 | +15.1% | 0.02% | +36.4% |
| Q2 2018 | $14,810,000 | -7.8% | 304,472 | +101.4% | 0.01% | -8.3% |
| Q1 2018 | $16,067,000 | -14.6% | 151,202 | -52.0% | 0.01% | -14.3% |
| Q4 2017 | $18,823,000 | +156.2% | 315,067 | +2.8% | 0.01% | +133.3% |
| Q3 2017 | $7,348,000 | +27.4% | 306,478 | +3.9% | 0.01% | +20.0% |
| Q2 2017 | $5,766,000 | -8.5% | 295,003 | +9.9% | 0.01% | 0.0% |
| Q1 2017 | $6,303,000 | +94.5% | 268,311 | +1.6% | 0.01% | +66.7% |
| Q4 2016 | $3,241,000 | +49.0% | 264,165 | +108.2% | 0.00% | +50.0% |
| Q3 2016 | $2,175,000 | +360.8% | 126,874 | +275.8% | 0.00% | – |
| Q2 2016 | $472,000 | +16.8% | 33,763 | +15.6% | 0.00% | – |
| Q1 2016 | $404,000 | -14.6% | 29,210 | +4.7% | 0.00% | -100.0% |
| Q4 2015 | $473,000 | +57.7% | 27,887 | 0.0% | 0.00% | – |
| Q3 2015 | $300,000 | +1.0% | 27,887 | +17.4% | 0.00% | – |
| Q2 2015 | $297,000 | +18.3% | 23,757 | +5.7% | 0.00% | – |
| Q1 2015 | $251,000 | -15.2% | 22,468 | +18.8% | 0.00% | – |
| Q4 2014 | $296,000 | +20.8% | 18,911 | -4.6% | 0.00% | – |
| Q3 2014 | $245,000 | – | 19,826 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |